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Structural and Functional Analysis
of the Costimulatory Receptor
Programmed Death-1
identity with CD28, CTLA-4, and ICOS. Currently, the
only two known sequences of PD-1 are the murine and
human orthologs that share 60% identity (Finger et
al., 1997). The engagement of PD-1 by its specific li-
gands, B7-H1 (PD-L1) (Dong et al., 1999) or B7-DC (PD-
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Albert Einstein College of Medicine based switch motif of the cytoplasmic tail of PD-1 and
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The Johns Hopkins University mice develop lupus-like autoimmune proliferative arthri-
tis and glomerulonephritis with IgG3 deposition (Nishi-Baltimore, Maryland 21218
mura et al., 1999), while deficiency of PD-1 in BALB/c
mice results in a severe autoimmune dilated cardiomy-
opathy followed by death due to congestive heart failureSummary
(Nishimura et al., 2001).
PD-1 and the other receptors in this family are allPD-1, a member of the CD28/CTLA-4/ICOS costimula-
tory receptor family, delivers negative signals that type I transmembrane glycoproteins composed of an Ig
Variable-type (V-type) extracellular domain, a trans-have profound effects on T and B cell immunity. The
2.0 A˚ crystal structure of the extracellular domain of membrane domain, and a cytoplasmic tail responsible
for the binding of signaling and scaffolding molecules.murine PD-1 reveals an Ig V-type topology with overall
similarity to the CTLA-4 monomer; however, there are CD28, CTLA-4, and ICOS are covalently linked homodi-
mers due to the interchain disulfide mediated by thenotable differences in regions relevant to function. Our
structural and biophysical data show that PD-1 is equivalent of Cys122 in CTLA-4 (Schwartz et al., 2002).
In contrast, PD-1 cannot form such a covalent dimer asmonomeric both in solution as well as on cell surface,
in contrast to CTLA-4 and other family members that it lacks the analogous Cys residue and it is not known
whether it forms noncovalent oligomers. In addition,are all disulfide-linked homodimers. Furthermore, our
structure-based mutagenesis studies identify the li- PD-1 possesses only a single intrachain disulfide in its
Ig V-type domain, while CD28, CTLA-4, and ICOS allgand binding surface of PD-1, which displays signifi-
cant differences compared to those present in the contain two intrachain disulfides. Another distinct fea-
ture of PD-1 is that the CDR3 loop does not contain theother members of the family.
conserved XXPPP(F/Y) (X represents any amino acid)
motif present in CD28, CTLA-4, and ICOS, which is
known to be critical for their ligand binding activities.T cell activation and regulation are critically dependent
on signals provided by members of the CD28/CTLA-4 Consistent with this sequence disparity, PD-1 does not
bind B7-1, B7-2, or B7RP-1, and it has not been estab-costimulatory receptor family. For example, CD28 and
ICOS, upon engaging their respective ligands (B7-1/ lished whether the CDR3 loop of PD-1 plays a role in
B7-2 and B7RP-1), deliver stimulatory signals that binding its own ligands B7-H1 and B7-DC (Latchman et
upregulate the activity of the responding T cells (Carreno al., 2001; Sharpe and Freeman, 2002). Furthermore, in
and Collins, 2002). In contrast, the binding of CTLA-4 to contrast to other receptors in this family that are only
the B7-1/B7-2 ligands negatively regulates T cell activity, present on T cell surfaces, PD-1 is also expressed on
resulting in decreased T cell proliferation and decreased the surface of activated B cells and plays a role in B
cytokine production. Programmed death-1 (PD-1) is an- cell regulation (Agata et al., 1996). Taken together, these
other member in this family, sharing 20% sequence distinct features of PD-1 set it apart as a unique member
of the costimulatory receptor family. Currently, there are
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cell surface. These observations establish differences
in oligomeric state between PD-1 and other members
of the costimulatory receptor family.
Results
PD-1 Is Monomeric in Solution
The extracellular Ig V-type domain of murine PD-1 was
expressed in E. coli and refolded in vitro. This purified
protein chromatographed as a symmetric monodisperse
peak on a calibrated Superdex G-75 (30X1.0) gel filtra-
tion column. The elution time of 17.5–18 min corre-
sponds to a molecular weight (MW) of 15 kDa (Figure
1A), which is very close to the calculated MW of 13296
Da for the recombinant PD-1 monomer. The similarly
refolded, purified human PD-1 protein (calculated MW
14501 Da) also ran as a15 kDa monomer on Superdex
G-75 gel filtration chromatography (data not shown).
The monomeric state of murine PD-1 in solution was
confirmed by sedimentation equilibrium analysis (Figure
1B). The data are consistent with a single component
model with values within error of the monomeric MW of
the recombinant murine PD-1. Various self-association
models (i.e., monomer ↔ dimer, monomer ↔ trimer,
and monomer ↔ tetramer) were examined and are not
consistent with the data. Taken together, these results
demonstrated that this soluble form of PD-1 is a stable
monomer and does not measurably oligomerize in so-
lution.
PD-1 Is Monomeric when Expressed
on the Cell Surface
To examine the oligomeric state of PD-1 in a cellular
context, the coding regions for the cyan fluorescent
protein (CFP) or yellow fluorescent protein (YFP) were
fused to the 3 end of the full-length murine PD-1 gene.
These constructs were cotransfected into CHO cells and
the oligomeric state of the full-length protein on the cell
Figure 1. Monomeric State of Murine PD-1 surface was evaluated using FRET by photobleaching
(A) Elution profile of the purified extracellular Ig V-type domain of (Figure 2A). The tandem CFP-YFP fusion protein and full-
murine PD-1 from Superdex G75 Gel filtration chromatography. The length disulfide-linked dimeric murine CTLA-4 served as
single monodisperse peak at 17.5–18 min corresponds to a MW
positive controls and gave a broad distribution of FRETof 15 kDa.
efficiencies with averages of 24%  8% and 16% (B) Determination of the oligomerization state of the Ig V-type do-
5%, respectively (Figure 2B). The data scatter is typicalmain of murine PD-1 by sedimentation equilibrium. Filled points
(closed circles) and open points (open circles) represent data col- of the CFP/YFP FRET pair (Pentcheva and Edidin, 2001).
lected at 25,000 rpm and 34,000 rpm, respectively. For clarity, every The FRET efficiency for the tandem CFP-YFP and disul-
sixth point is plotted. Lines represent the best fit to a single-compo- fide-linked CTLA-4 showed no dependence on acceptor
nent sedimentation model yielding an estimate of the apparent MW,
intensity (Figure 2C). This behavior is characteristic of a13.3 kDa. The residuals of the corresponding points are randomly
system containing preassociated (i.e., clustered) donor/distributed, indicating that there is no oligomerization occurring and
acceptor molecules, and is fully consistent with the co-that the sample only consists of monomers.
valent structure of these molecules (Kenworthy and
Edidin, 1998). The distribution of FRET efficiencies for
the full-length PD-1 constructs is greatly skewed towardWe report here the structural, biophysical, and bio-
chemical features of the Ig V-type domain of murine lower values (relative to the positive controls) with an
average value of 6%  4%, slightly but significantlyPD-1. The crystal structure and structure-based muta-
genesis studies of PD-1 identified a ligand binding sur- higher than the FRET observed for the negative control
(Figure 2B). FRET between CPF-PD-1 and YFP-PD-1face that is significantly different from those of the other
members of the CD28/CTLA-4 costimulatory receptor molecules showed a linear dependence on acceptor
fluorescence intensity (Figures 2B and 2C). This is char-family. In addition, our data demonstrate that this solu-
ble form of PD-1 is monomeric both in solution and the acteristic of FRET between randomly distributed mole-
cules and is consistent with the presence of unclusteredcrystalline form. More importantly, fluorescence reso-
nance energy transfer (FRET) studies demonstrate that (i.e., monomeric) PD-1 on the cell surface (Kenworthy
and Edidin, 1998). A short form of PD-1 with the cyto-full-length PD-1 is monomeric when expressed on the
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Figure 2. Cellular Behavior of PD-1
(A) Images of CFP and YFP fluorescence on individual cells pre- and postbleaching. For clearer presentation, the color scheme of the images
is reversed with CFP and YFP displayed in red and blue, respectively.
(B) Distribution pattern of FRET efficiency (x-axis) as a function of number of cells (y-axis) for various groups as labeled. These data are
pooled from four independent experiments, with total 14, 15, 21, and 25 cells examined for the tandem CFP-YFP, CTLA-4, L-PD-1, and S-PD-
1, respectively. NC, negative control.
(C) The correlation between the acceptor intensity (expressed as arbitrary units) and the FRET efficiency for individual regions of interest (ROI)
is shown for the groups as marked. The total number of ROI analyzed for each group is 60 to 80. The line corresponds to the best linear fit
and its slope is the measure of dependence of FRET efficiency on the concentration of acceptor molecules (expressed as acceptor intensity)
(Kenworthy and Edidin, 1998).
plasmic tail trimmed to 10 residues displayed spectral our recombinant murine PD-1 specifically binds B7-H1-
Ig coupled to CM5 sensor chips, suggesting that PD-1properties similar to the long form (Figures 2B and 2C),
suggesting that the behavior of the full-length wild-type refolded from inclusion bodies is biologically active.
Equilibrium binding assays were performed to deter-murine PD-1 is not due to the long (94 amino acids),
and likely flexible, cytoplasmic tail. Together the data mine the equilibrium dissociation constant (Kd) between
murine PD-1 and the B7-H1-Ig fusion protein. Murinestrongly support the idea that PD-1 is predominantly
present as a monomer on the cell surface. PD-1, over a wide range of concentrations (78.0–0.5
M), was sequentially injected over the sensor chip cou-
pled with murine B7-H1-Ig (Figure 3A). At all concentra-Binding Affinity of the Murine PD-1/B7-H1 Complex
In order to test whether the recombinant PD-1 produced tions examined, binding reached equilibrium within a
few seconds, and similarly, complete dissociation wasin bacteria retains its biological activity, the interaction
between murine PD-1 and the B7-H1-Ig fusion protein achieved within a few seconds after termination of the
injections. These observations are consistent with fastwas measured by surface plasmon resonance (SPR) us-
ing a Biacore X instrument. The results demonstrate that kon and koff rates for the PD-1/B7-H1 interaction. Nonlin-
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CDR1 loops between PD-1 and CTLA-4 are largely due
to their different lengths as shown by the structure-
based sequence alignment (Figure 5C). Although the
difference in the CDR3 loop between PD-1 and CTLA-4
is less obvious based on the superimposition, detailed
structural analyses highlight fundamental differences in
this region. In the crystal structures of both murine and
human CTLA-4, the CDR3 loops are very rigid as indi-
cated by well-defined electron density and relatively low
Figure 3. Equilibrium Binding Affinity Measurement for Murine PD- B factors in this region compared to the rest of the
1/B7-H1-Ig protein (Ostrov et al., 2000; Schwartz et al., 2001;
(A) Murine PD-1 over a series of concentrations (started from 78.0 Stamper et al., 2001). This is in part due to the three
M and 1.4-fold dilution thereof) was injected over both the experi- consecutive Pro residues in the CDR3 loop (99MYP-mental flow cell (containing 3621 RUs immobilized murine B7-H1-Ig)
PPY104) that adopt an unusual cis-trans-cis conformationand the reference flow cell. The final response at each concentration,
that is critical for the ligand binding activity of CTLA-4.represented by the continuous sensorgrams, was obtained by sub-
tracting the response of the control cell from that of the experimen- In contrast, the CDR3 loop in the present PD-1 structure
tal cell. displays very high B factors and weak electron density
(B) Nonlinear 1:1 Langmuir fitting and linear Scatchard plot (insert) compared to the rest of the molecule, indicating this
of the binding data yield Kd of 4.17 0.14 and 3.9 0.07M, respec- loop in PD-1 is highly flexible.tively.
Notably, nonpolar residues in the front sheet of PD-1
(M31, L32, A47, A48, I93, L95, P97, A99, and I101) form
a large hydrophobic patch surrounded by hydrophilicear 1:1 Langmuir fitting of the binding data yielded a Kd
residues, including charged residues D29, K45, K98, andof 4.17  0.14 M, and linear fitting of the Scatchard
E103 (Figures 4B and 4C), which is reminiscent of theplot of the same data resulted in a Kd of 3.90  0.07 M
organization present in classical protein-protein inter-(Figure 3B). These equilibrium constants observed for
faces (Bogan and Thorn, 1998). In addition, these nonpo-PD-1/B7-H1 are comparable to those measured for the
lar residues are highly conserved between murine andCTLA-4/B7 complexes using similar SPR assays (Collins
human PD-1 (Figure 5C). These observations, in combi-et al., 2002). Crossspecies interaction of human PD-1
nation with the fact that other members in this familywith murine B7-H1 has been reported before by several
(CD28, CTLA-4, and ICOS) all use their front face forstudies (Freeman et al., 2000; Latchman et al., 2001).
ligand binding (Schwartz et al., 2001; Stamper et al.,These observations were confirmed by the same SPR
2001; Wang et al., 2002), suggest that this hydrophobicbinding assay that demonstrated that recombinant mu-
patch on the front face might be the predominant deter-rine and human PD-1s exhibited roughly similar binding
minant for ligand binding in PD-1. Another hydrophobicaffinity for murine B7-H1-Ig (data not shown).
patch on the surface of murine PD-1 formed by residues
in the AA loop is involved in a crystal contact in theThe Structure of Murine PD-1 and a Comparison
present crystal form. However, residues forming thiswith that of CTLA-4
hydrophobic patch are not conserved between murineThe PD-1 monomer displays a two-layer  sandwich
and human PD-1 and there is no evidence supportingtopology characteristic of Ig V-type domains, with the
a role for this region in PD-1 function (Figure 5C).front and back sheets formed by the AGFCCC″ and
ABED strands, respectively (Figure 4A). Cys21 in the B
strand and Cys90 in the F strand form an intrachain Ligand Binding Surface of Murine PD-1
Based on the crystal structures of murine PD-1 and thedisulfide, which is a hallmark feature of Ig V-type do-
mains (Metzler et al., 1997). An examination of contacts CTLA-4/B7 complexes (Schwartz et al., 2001; Stamper
et al., 2001), a series of murine PD-1 mutants (D29A,within the crystal does not identify any candidate dimer
interface, consistent with the observed monomeric state D29S, M31A, N33A, K45A, N51A, L53A, Q55A, Q55S,
V57A, H74S, R81S, I93A, L95A, H96A, P97A, K98A, A99L,of PD-1 in solution and on the cell surface.
Although there is only about 20% sequence identity I101A, and E103A) were designed for mapping its ligand
binding surface. While most of the selected residuesbetween their extracellular Ig V-type domains, a super-
imposition of the structures of murine PD-1 and CTLA-4 were mutated to Ala, several polar residues were mu-
tated to Ser to minimize adverse effects of the mutationmonomers demonstrates that they have very similar
overall structures as evidenced by the good overlay on protein refolding and stability. All of the residues
selected for mutagenesis have their side chains directedbetween most of the equivalent  strands (Figures 5A
and 5B) (Ostrov et al., 2000). This structural similarity is toward solvent, and therefore, their mutations are pre-
dicted not to significantly affect the hydrophobic coreconfirmed by the low root mean square (rms) deviation
of 1.5 A˚ between 76 equivalent C atoms from PD-1 or structural integrity of the PD-1 protein. The majority
of these residues are located in or near the hydrophobicand CTLA-4. However, there are significant differences
between PD-1 and CTLA-4 involving the C″ strand, CC″ patch on the front face (Figure 1B). All of the mutants
except Q55A and I93A were expressed, refolded, andC″D and CDR1 loops. The most pronounced difference
is the placement of the C″ strand that participates in purified at yields comparable to the wild-type. Q55A did
not refold under the conditions used to refold the otherthe back face in CTLA-4 but participates in the front
face in PD-1. Structural differences in the CC″, C″D and proteins, which may be the consequence of the in-
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Figure 4. Structure of Murine PD-1
(A) Ribbon diagram of the Ig V-type domain of murine PD-1. The front (green) and back (aqua) sheets are composed of AGFCCC″ and ABED
strands, respectively. The CDR3 loop is labeled. The intrachain disulfide is shown in yellow. The four potential glycosylation sites are highlighted
by showing the side chains of the Asn residues in red.
(B) Hydrophobicity of the molecular surface of murine PD-1. Hydrophobic residues are colored in yellow, whereas hydrophilic residues are
colored in red. The orientation of the molecule is similar to that in (A). The large hydrophobic patch on the front face (circled) was hypothesized
to be the ligand-binding site.
(C) Electrostatic molecular surface of murine PD-1. Negative and positive potentials are colored in red and blue, respectively. Charged residues
surrounding the hydrophobic patch shown in (B) are labeled. The orientation of the molecule is similar to that in (A).
creased hydrophobicity of the protein surface intro- The mutants can be divided into several groups based
on their abilities to bind the B7-H1 ligand. K45A, I93A,duced by the mutation, since the Q55S mutant refolded
just as well as the wild-type. I93A had a significantly L95A, I101A, and E103A have unmeasurable or ex-
tremely weak binding activity for the ligand comparedlower refolding yield compared to the wild-type and
other mutants, but it was reasonably stable after refold- to the wild-type (Figure 6; see Supplemental Table S2
at http://www.immunity.com/cgi/content/full/20/3/337/ing and adequately well behaved for binding assays.
The lower refolding efficiency of I93A might be the con- DC1), suggesting side chains of these residues are di-
rectly involved in and indispensable for the interactionsequence of a localized structural perturbation caused
by the mutation, as I93 is located at the center of the between PD-1 and B7-H1. M31A, N33A, H96A, and K98A
display significantly reduced binding compared to thehydrophobic patch. The purified HA-tagged wild-type
and all the refolded mutants eluted as monodisperse wild-type (around 42%–67% of wild type) (Figure 6; Sup-
plemental Table S2), suggesting that they directly partic-peaks from the Superdex G-75 column at 17 min,
slightly earlier than the elution time of the nontagged ipate in, but are not absolutely required for, ligand bind-
ing. Consistent with their important roles in ligandPD-1 (not shown), consistent with the higher MWs of
these epitope tagged proteins. Comparable refolding binding, all of the altered residues in these mutants,
except M31 and H96, are identical in human and murineefficiency and similar behavior on gel filtration chroma-
tography suggest that these mutants refolded correctly PD-1 (Figure 5C). Sequence conservation of residues
important for ligand binding between murine and humanand have the same overall structure as the wild-type of
murine PD-1. Therefore, the measured differences in PD-1 indicates that murine B7-H1 recognizes similar
binding surfaces on murine and human PD-1, in agree-binding affinities for the mutants, compared to the wild-
type, should directly reflect the contributions of particu- ment with the observed similar binding of B7-H1 by
these two receptors.lar residues to the ligand binding activity of murine PD-1.
The binding activities of the HA-tagged and non- Q55S, V57A, and P97A have moderately decreased
affinities for the ligand compared to the wild-typetagged wild-type PD-1 were compared by injecting
these two proteins at the same concentration over the (around 83%–88% of wild type), whereas N51A and
L53A bind the ligand as well as the wild-type of PD-1same CM5 sensor chip coupled with murine B7-H1-Ig,
which resulted in very similar response levels (data not (Figure 6; Supplemental Table S2). Interestingly, D29A,
D29S, and A99L display approximately 10%–20% highershown). This result indicates that the HA-tag does not
significantly affect the binding activity of PD-1 for its binding to the ligand than the wild-type (Figure 6; Sup-
plemental Table S2). The observation that the A99L mu-ligand. Therefore, all subsequent binding assays utilized
the HA-tagged wild-type and mutants of murine PD-1. tation increased rather than abolished ligand binding
was surprising, as it was predicted that the substitutionThe wild-type and mutant proteins, at the same concen-
tration, were sequentially injected over the sensor chips of Ala with a bulky Leu residue would cause steric hin-
drance in the binding interface, and consequently, pre-coupled with murine B7-H1-Ig fusion protein, and the
response levels of the mutants were compared with that vent PD-1 from interacting with B7-H1. However, con-
sidering the high inherent flexibility of the CDR3 loopof the wild-type to obtain the relative ligand binding
activities of the mutants. suggested by the crystal structure, the bulky side chain
Immunity
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Figure 5. Comparison of Murine PD-1 and CTLA-4
(A and B) Two orthogonal views of a superimposition of murine PD-1 (green) and CTLA-4 (gray) structures. Parts with significant differences
between the two structures are labeled.
(C) Structure-based sequence alignment of PD-1 and CTLA-4. Identical residues between murine and human PD-1 are colored in yellow,
whereas invariant residues between PD-1 and CTLA-4 are colored in red. Residues in murine PD-1 selected for mutation are highlighted with
closed squares in blue. Residues in CTLA-4 involved in homodimerization and B7 binding (the MYPPPY loop) are highlighted with closed
circles and closed squares, respectively. Cys122 mediating the interchain disulfide in CTLA-4 is highlighted with closed circles in green; a
Glu residue occupies the equivalent position in PD-1.
of Leu99 might be readily accommodated by a local (Schwartz et al., 2001; Stamper et al., 2001) and the
conformational adjustment upon the engagement of the disulfide-linked dimer of unliganded CTLA-4 (J.-C.D.S.
ligand. Notably, the double mutant D29A/A99L exhibits and X.Z., unpublished data) have shown that the dimer-
approximately 35% higher ligand binding than the wild- ization interface of CTLA-4 is formed by nearly invariant
type, suggesting an additive effect caused by the D29A residues located C-terminal to the G strand and residues
and A99L single mutations (Figure 6E; Supplemental centered around the A strand. (Figure 5C). The analo-
Table S2). Taken together, these results demonstrate gous regions in PD-1 are not highly conserved between
that the residues altered in these mutants do not contrib- human and murine sequences (60% identity in these
ute significant binding energy to the PD-1/B7-H1 inter- regions versus 65% identity in the whole extracellular
action. H74S and R81S, located on the back sheet and domain) (Figure 5C), suggesting that these regions do
the interface between the front and back sheets, respec- not play a central role in the structure and function of
tively, both exhibit ligand binding activities similar to the PD-1. It should be noted that even in the absence of the
wild-type (Figures 6E and 6F; Supplemental Table S2). interchain disulfide, a significant proportion of CTLA-4
These observations are consistent with the conclusion exists as a noncovalent dimer in solution, demonstrating
that the ligand binding surface resides solely on the its inherent tendency to self-associate (Zhang et al.,
front face of PD-1 (Figure 7A). 2002). These observations imply an intrinsic difference
between PD-1 and CTLA-4, and by extension, perhaps
CD28 and ICOS as well. Importantly, the dimeric natureDiscussion
of the CTLA-4 and B7 molecules are critical features of
the alternating lattice of the CTLA-4/B7 complexes thatThe present study shows that PD-1 is monomeric both
have been proposed to play a role in CTLA-4-mediatedin solution and on the cell surface, in contrast to CTLA-4,
signal transduction (Schwartz et al., 2001; Stamper etCD28, and ICOS, which are all obligate disulfide-linked
al., 2001). Therefore, the monomeric nature of PD-1 sug-homodimers (Carreno and Collins, 2002; Schwartz et
al., 2002). The structures of the CTLA-4/B7 complexes gests that this molecule might signal through a distinct
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Figure 6. Ligand-Binding Activities of the Murine PD-1 Mutants
The wild-type and mutants of HA-tagged murine PD-1 at 1.7 M were injected at 20 l/min for 2 min over CM5 sensor chips coupled with
murine B7-H1-Ig fusion protein. The final response of each protein was calculated by subtracting the response of the control cell from that
of the experimental cell. The response levels of the mutants were compared with that of the wild-type protein to obtain the relative ligand-
binding activities of the mutants.
mechanism, such as ligand-induced dimerization, oligo- G strands, which are identified by our mutagenesis stud-
ies as major contributors to the ligand binding surface.merization, or conformational alterations. However, at
present, a more detailed model of the signaling complex Glycosylation of this site might influence the local struc-
ture, and consequently, could have some impact on thecannot be proposed since there are no data regarding
the in vitro or in vivo oligomerization state of the PD-1 affinity of PD-1 for ligand. The qualitative features of the
binding and dissociation phases of the sensorgramsligands. While the present studies demonstrate that a
significant fraction of the PD-1 molecules exist as mono- suggest that the kon and koff of the PD-1/B7-H1 interac-
tion are rapid, similar to that observed for the CTLA-4/mers on the cell surface, the spectroscopic techniques
utilized cannot rule out the presence of a small and B7 complexes (Figure 3) (Collins et al., 2002).
The crystal structure of PD-1 provided critical informa-transient population of clustered PD-1 molecules, as has
been recently demonstrated for CD40 (Reyes-Moreno et tion for rational mutagenesis studies, which resulted in
an outline of the ligand binding surface on this costimu-al., 2003).
Receptor/ligand binding assays demonstrate that latory receptor. The hydrophobic residues identified to
be critical for ligand binding (I93, L95, and I101) all clus-bacterially expressed murine PD-1 lacking carbohydrate
binds to murine PD-L1-Ig fusion protein with a Kd of 4 ter in the hydrophobic patch on the front face of murine
PD-1. These residues are surrounded by the threeM. These observations demonstrate that, as has been
previously shown for human CTLA-4 and B7-2 (Schwartz charged residues (K45, K98, and E103) and two polar
residues (N33 and H96) that are also involved in the PD-et al., 2001; Stamper et al., 2001; Zhang et al., 2002),
glycosylation is not required for the ligand binding activ- 1/B7-H1 interaction (Figures 1 and 7). The hydrophobic
center (I93, L95, and I101) and charged residues (K45ity of PD-1. There are four potential glycosylation sites
in the Ig V-type domain of murine PD-1. Three of these and E103) contribute significant binding energy to the
receptor/ligand interaction, as indicated by the com-four sites, N16 (in the AB loop), N41 (in the CC loop)
and N83 (in the EF loop), are located distal to the ligand plete loss of ligand binding upon the mutation of these
residues. Other polar residues surrounding the hy-binding surface on the front face and most likely do
not directly affect ligand binding of PD-1 (Figure 1A). drophobic patch (N33, H96, K98) may mainly function
in stabilizing the orientation between the receptor andHowever, glycosylation of these sites in vivo could pro-
vide restraints on the orientation of PD-1 on the cell ligand and determining the specificity of the interaction,
as mutation of these residues results in reduced, butsurface and indirectly affect PD-1/PD-L interaction in
the immunological synapse, as has been previously sug- not abolished, ligand binding. The ligand binding surface
in CTLA-4 is also composed of a cluster of hydrophobicgested for CD2 and ICAM-2 (Davis et al., 1998; Wang
and Springer, 1998). The fourth site, N25, located in the residues (the MYPPPY CDR3 loop) and several hydro-
philic residues (E33, R35, T53, and E97) (Figure 7B)CDR1 loop (BC loop) is in close proximity to the F and
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studies show that residues in the CDR3 loop of murine
PD-1 are not critical determinants for the PD-1/B7-H1
interaction. None of the four residues selected for muta-
genesis (H96, P97, K98, and A99) in the CDR3 loop are
absolutely required for ligand binding of PD-1 (Figure
7A; Supplemental Table S2). Consistent with their mod-
est roles in ligand binding, residues in the CDR3 loop
are not strictly conserved between murine and human
PD-1 (Figure 5C). In contrast, the residues identified to
be critical for ligand binding (K45, I93, L95, I101, and
E103) are all contributed from strands in the front face.
Interestingly, a recent mutagenesis study on the li-
gands of murine PD-1 has also shown that residues
from the strands on the front faces, but not those in
the CDR3 loops, of both murine B7-H1 and B7-DC are
required for binding PD-1(Wang et al., 2003). Taken to-
gether, these mutagenesis data on both the receptor
and ligands suggest that the complexes of PD-1 and its
ligands adopt an orthogonal binding mode similar to
that of the CD2/CD58 complex (Wang et al., 1999) such
that strands from the front faces of the receptor and
ligands make the major contribution to the receptor/
ligand interface, whereas the CDR3 loops reside at the
periphery of the interface and do not make critical
atomic contacts. This interpretation suggests a strand-
to-strand binding mode for the PD-1/PD-L complexes,
which is distinct from the loop-to-strand binding mode
observed in the CTLA-4/B7 complexes and also thought
to be relevant to the CD28/B7 and ICOS/ B7RP-1 costi-
mulatory complexes (Schwartz et al., 2001; Stamper et
al., 2001).
The mutagenesis study has also identified a few PD-1
Figure 7. Comparison of Ligand-Binding Surfaces of PD-1 and mutants (D29A, D29S, A99L, and D29A/A99L) with
CTLA-4 slightly improved binding to the ligand compared to the
(A) Molecular surface of murine PD-1. Residues whose mutations wild-type. The observation of these moderately higher
resulted in abolished or significantly reduced ligand binding are affinity mutants suggests the possibility of designing
colored in red, whereas residues whose mutations had no significant
additional PD-1 mutants with even higher ligand bindingeffects on ligand binding or led to higher ligand binding are colored
affinities. Given the recent implication of PD-1 signalingin gray. The ribbon diagram is shown on the right to indicate the
orientation of the molecule. in tumor immune evasion (Dong et al., 2002; Iwai et
(B) Molecular surface of human CTLA-4 from the CTLA-4/B7-2 com- al., 2002), such reagents may prove valuable for the
plex (Schwartz et al., 2001). Residues involved in ligand binding are development of immuno-therapy against various malig-
colored in red. The ribbon diagram is shown on the right to indicate nancies.
the orientation of the molecule. The CDR3 loops in both PD-1 (A)
In summary, PD-1 has been shown to be monomericand CTLA-4 (B) are circled and labeled, showing the different contri-
both in solution and when expressed on the cell surface.butions of this loop to ligand binding for these two receptors.
In addition, structure-based mutagenesis studies have
identified the unique surface of PD-1 responsible for
binding ligand. These findings suggest significant struc-(Schwartz et al., 2001; Stamper et al., 2001). However,
tural and functional differences between PD-1 and otherthis surface of CTLA-4 is organized differently, in that the
members of the costimulatory receptor family.hydrophilic residues are located close to one another,
forming a patch that is adjacent to the hydrophobic area.
A more notable difference between the ligand binding Experimental Procedures
surfaces of PD-1 and CTLA-4 is the role of the CDR3
Cloning, Expression, and Purification of the Extracellularloop in ligand binding. Structural studies reveal that the
Ig V-Type Domains of Murine and Human PD-1CDR3 loop of CTLA-4 is a major contributor to the bind-
The extracellular region of murine PD-1 with the unpaired Cys50
ing interface and mutagenesis studies demonstrate that mutated to Ser was amplified by two-step PCR using the full-length
these residues are indispensable for ligand binding murine PD-1 cDNA as the template as described for ICOS by Wang
et al. (2002). The flanking 5 primer (incorporating an NdeI site and(Metzler et al., 1997; Morton et al., 1996; Schwartz et
the start codon) and 3 primers (incorporating a BamHI site) wereal., 2001; Stamper et al., 2001). The CDR3 loop of CTLA-4
5GAGGCTCATATGTCCCTCACCTTCTACCCAGCC3 and 5ACGGadopts an unusual cis-trans-cis conformation and is
GATCCTCACTCCAGGATTCTCTCTGTTAC3, respectively. The twovery rigid, as shown by all the available crystal structures
middle complementary primers containing the Cys to Ser mutation
of CTLA-4. In contrast, the CDR3 loop of PD-1 exhibits were 5ACTGAAAAACAGGCCGCCTTCTCTAATGGTTTGAGCCAAC
considerable flexibility with weak electron density and CCGTC3 and 5GACGGGTTGGCTCAAACCATTAGAGAAGGCGGC
CTGTTTTTCAGT3. The PCR product was sequenced and clonedrelatively high B factors. Furthermore, mutagenesis
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into pET3a vector predigested with NdeI and BamHI as described tor with a 5 kDa cut-off membrane before the experiments. Sedimen-
for B7-2 previously (Zhang et al., 2002). Using this pET3a vector tation equilibrium analysis was performed at protein concentrations
containing the PD-1 insert as the template, a HA-tagged derivative of 11.3, 22.6, and 37.6 M (0.15, 0.3, and 0.5 mg/ml) in a Beckman
of wild-type murine PD-1 was amplified by PCR. The same flanking analytical ultracentrifuge using an AN-60 Ti rotor at 4C. The partial
5 primer was used. The flanking 3 primer (including the sequences specific volume of murine PD-1 was calculated to be 0.721 cm3 g–1
that encode 3 linker residues and the HA tag) was 5GTAGGATCCT based on the amino acid composition. Buffer density was deter-
CAAGCGTAGTCTGGAACATCATACGGGTAGGAGCCACCTGAGGT mined to be 1.0040 cm3 g–1 using a Mettler De40 density meter
CTCCAGGATTCTCTC3. The same mutagenesis strategy was em- operated at the experimental temperature. Absorbance scans were
ployed to amplify the HA-tagged mutants of PD-1 (D29A, D29S, taken after 24 and 26 hr and equilibrium was assumed to have been
M31A, N33A K45A, N51A, L53A, Q55A, Q55S, V57A, H74S, R81S, reached if the results were unchanged. Data were collected at rotor
I93A, L95A, H96A, P97A, K98A, A99L, I101A, and E103A) for ligand speeds of 25,000 rpm and 34,000 rpm after equilibrium was reached
binding assays using middle complementary primers containing de- and analyzed using Beckman XL-A/XL-I software v4. Analyses con-
sired mutations. A D29A/A99L double mutant was generated using sisted of six scans taken of the three different nominal concentra-
the D29A pET3a plasmid as the template. The extracellular Ig V-type tions at each of the two rotor speeds.
domain of human PD-1 (129 amino acid residues excluding the
initiator Met) was also cloned with the unpaired Cys60 mutated to SPR Binding Assays for PD-1 and B7-H1-Ig Fusion Protein
Ser. The flanking 5 primer and 3 primers were 5GAGGCTCATATG All binding experiments were carried out using a BIAcore X optical
TGGAACCCCCCCACCTTCTCC3 and 5GTAGGATCCTCAGGGT biosensor at 25C. Research grade CM5 sensor chips were activated
GAGGGGCTGGGGTGGGC3, respectively. The two middle comple- by a 7 min injection of a 1:1 mixture of NHS and EDC from the amine
mentary primers containing the Cys to Ser mutation were 5CGCAG coupling kit at a flow rate of 5 l/min. 7–15 l of mB7-H1-Ig fusion
CCAGCCCGGCCAGGACTCCCGCTTCCGTGTCACACAACTG3 and protein (50g/ml) in 10 mM acetate buffer (pH 5.0) were injected over
5CAGTTGTGTGACACGGAAGCGGGAGTCCTGGCCGGGCTGGCT the experimental flow cell and immobilized to the sensor surface by
GCG3. The HA-tagged versions of the wild-type and mutants were free amine coupling chemistry, which typically resulted in immobili-
prepared as they represent a highly useful reagent set for future ex- zation levels of 3500–4000 RUs. 35 l of 1 M ethanolamine (pH 8.5)
periments.
was then injected for 7 min to deactivate both the experimental and
The proteins were expressed and refolded as described for B7-2
reference flow cells. A sensor chip coupled with a misfolded murine
(Zhang et al., 2002). The wild-type murine PD-1 was purified by
B7-DC protein produced in the lab was used as a negative control
gel filtration (Superdex G75, 30X1.0) followed by anion exchange
for the binding assays. For determining the binding affinity of the(MonoQ, 1 ml) chromatography to produce protein of 99% purity
wild-type murine PD-1 for mB7-H1-Ig, 16 serial dilutions of the PD-1for crystallization. The HA-tagged wild-type and mutants of murine
protein, starting from 78.0 M and 1.4-fold dilution thereof, werePD-1 were purified to 95% homogeneity by gel filtration chroma-
prepared in HBS-EP buffer composed of 10 mM HEPES (pH 7.4),tography for SPR receptor/ligand binding assays. Human PD-1 was
150 mM NaCl, 3 mM EDTA, and 0.005% surfactant P20. Proteinsimilarly purified by gel filtration chromatography.
samples of different concentrations were sequentially injected over
both flow cells at a flow rate of 20 l/min for 2 min. BackgroundFRET Analyses for Murine PD-1 on the Cell Surface
responses of the reference flow cell were subtracted from the totalFull-length murine PD-1 was amplified by PCR using a 5-primer:
responses of the experimental flow cell to give the final response5ATCAGATCTGCCACCATGTGGGTCCGGCAGGTACCC3 and 3-
levels. Each experiment was repeated three times and the averageprimer: 5GGCGACCGGTGGAAGAGGCCAAGAACAATGTCC3. A
was taken as the final result. Purified human B7-2 Ig V-type domainshort version of murine PD-1 with the cytoplasmic tail trimmed to
at various concentrations in HBS-EP buffer was injected as negative10 residues was amplified using a 3-primer: 5GGCGACCGGTG
control, which resulted in response levels of 0 RU. Murine PD-1GAGTGTCGTCCTTGCTTCCAGC3. The PCR products were double
was injected to the negative control sensor chip, which also gener-digested with BglII and AgeI and cloned into predigested pECFP
ated response levels of 0 RU. These results confirm that the de-and pEYFP vectors. The sequences of the genes were confirmed
tected binding is the specific interaction between PD-1 and theby DNA sequencing. Full-length murine CTLA-4 was also cloned
ligand. Equilibrium dissociation constants were obtained by fittinginto the same set of vectors and used as positive controls. Tandem
the data using nonlinear 1:1 Langmuir binding model and linear 1:1CFP-YFP protein, another positive control, was made by fusing
binding Scatchard plot. The following equations were used for themurine B7-1 to 5 end of CFP, which in turn was cloned into pEYFP
nonlinear and linear fits:vector. In this tandem CFP-YFP construct, the CFP and YFP are
expressed on a single polypeptide chain separated by seven amino
R  RmaxC/(C 	 Kd) (non-linear 1:1 Langmuir binding model)acid residues. The CFP and YFP constructs were cotransfected
using Fugene 6 (Roche Biochemicals) into CHO cells grown on cover
R/C  
C/Kd 	 Rmax/Kd (linear 1:1 Scatchard plot)slips. 24–36 hr posttransfection, cells were fixed with 2% paraform-
aldehyde and examined with a Leica TCS SP 2 AOBS laser-scanning Where R is the bound analyte in RUs, Rmax is the maximum response
confocal microscope. CFP was excited with 405 nm light and emis- level, C is the concentration of free analyte in M, and Kd is the
sion monitored over the range of 416–492 nm; YFP was excited with equilibrium dissociation constant in M.
514 nm light and emission monitored over the range of 525–600 nm. The HA-tagged mutants of murine PD-1 were injected and the
YFP was photobleached using the 514 nm laser line at full power response levels were compared with that of the HA-tagged wild-
for 1–2 min. An image of CFP fluorescence and YFP fluorescence type protein injected at the same concentration to obtain the relative
after photobleaching was obtained using the respective filter sets.
ligand binding abilities of the mutants. A protein concentration of
Data were collected from 10–12 different cells in different fields from
1.7M (0.025 mg/ml) was used in these assays because this concen-
the same coverslip. Two to three regions of interest (located on the
tration of wild-type protein yielded high enough, but far from saturat-
cell membrane) in the photobleached area were selected per cell
ing, levels of SPR response shown by the experiments for affinityand the mean CFP fluorescence before and after photobleaching
measurement. All of the experiments were repeated at least twowas obtained using the Leica Confocal software. FRET efficiency
times and the differences between the repeats were negligiblewas calculated using the following relationship: FRETeff (Dpost-Dpre)/
(1%). The cross-species interaction of human PD-1 with murineDpost where Dpost is the fluorescence intensity of the CFP (donor; D)
B7-H1-Ig fusion protein was measured using the same protocol.after photobleaching and Dpre is the fluorescence intensity of the CFP
before photobleaching. A FRET efficiency of 5% was considered as
Crystallization, Data Collection, and Structure Determinationthe threshold for establishing a significant signal. Students t test
Murine PD-1 was crystallized by the hanging drop vapor diffusion(two tailed) was performed to demonstrate the level of significance
method by mixing 2l of protein at 6 mg/ml and 2l of crystallizationbetween various groups.
buffer composed of 20%–30% PEG 8000, 100 mM NaAc, and 100
mM NaCacodylate (pH 6.5). Crystals were flash cooled to 100 KAnalytical Ultracentrifugation Analyses for Murine PD-1
under a stream of nitrogen gas in the crystallization buffer supple-Purified murine PD-1 was exchanged into a buffer containing 10
mM Tris-HCl and 100 mM NaCl (pH 8.0) using an Amicon concentra- mented with 15% Glycerol before data collection. Diffraction data
Immunity
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from a single crystal were collected to 2.0 A˚ resolution at beamline member of the B7 family, co-stimulates T-cell proliferation and in-
terleukin-10 secretion. Nat. Med. 5, 1365–1369.X9B (National Synchrotron Light Source, Brookhaven National Labo-
ratory) using a 2X2 ADSC CCD Detector. The data were consistent Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies,
with the orthorhombic space group P212121 (a  23.97, b  50.80, D.B., Roche, P.C., Lu, J., Zhu, G., Tamada, K., et al. (2002). Tumor-
c  75.28 A˚). Data were processed with the HKL suite (Otwinowski associated B7–H1 promotes T-cell apoptosis: a potential mecha-
and Minor, 1997) and data collection statistics are summarized in nism of immune evasion. Nat. Med. 8, 793–800.
Supplemental Table S1.
Evans, S.V. (1993). SETOR: hardware-lighted three-dimensionalA BLAST search of the NCBI database suggested that the Ig
solid model representations of macromolecules. J Mol Graph 11,V-type domain of a TCR chain (V-2.6) was the most homologous
134–138.molecule to PD-1 (25% identity). The crystal structure of this Ig
V-type domain (PDB Number 1B88), with all of the nonidentical Finger, L.R., Pu, J., Wasserman, R., Vibhakar, R., Louie, E., Hardy,
R.R., Burrows, P.D., and Billips, L.G. (1997). The human PD-1 gene:residues between the model and PD-1 mutated to Ala or kept un-
changed if the original residue is a Gly, was used as the search complete cDNA, genomic organization, and developmentally regu-
lated expression in B cell progenitors. Gene 197, 177–187.model for molecular replacement trials performed with the program
EPMR at 4.0 A˚ resolution (Kissinger et al., 1999). The best solution Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishi-
with a single monomer of the model molecule from molecular re- mura, H., Fitz, L.J., Malenkovich, N., Okazaki, T., Byrne, M.C., et al.
placement has a correlation coefficient of 0.25 as calculated by (2000). Engagement of the PD-1 immunoinhibitory receptor by a
EPMR. Rigid body refinement of this model at 2.2 A˚ resolution using novel B7 family member leads to negative regulation of lymphocyte
the program CNS (Brunger et al., 1998) resulted in an Rfactor of 54.4%. activation. J. Exp. Med. 192, 1027–1034.
Despite the high Rfactor, a 2Fo-Fc electron density map calculated at
Gouet, P., Courcelle, E., Stuart, D.I., and Metoz, F. (1999). ESPript:2.2 A˚ resolution was readily interpretable, with continuous densities
analysis of multiple sequence alignments in PostScript. Bioinformat-for most of the strands. Modeling and refinement at 2.0 A˚ resolution
ics 15, 305–308.(including torsion angle dynamic simulated annealing, bulk solvent
correction, and individual B factor refinement) were performed by Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., and Minato,
N. (2002). Involvement of PD-L1 on tumor cells in the escape fromusing the program O (Jones et al., 1991) and CNS, respectively. The
final model contains all the residues of murine PD-1, except the host immune system and tumor immunotherapy by PD-L1 blockade.
Proc. Natl. Acad. Sci. USA 99, 12293–12297.C-terminal residue Glu and the side-chains of His96, Pro97, and
Lys100, and 73 H20 molecules, with Rcryst and Rfree of 19.82% and Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. (1991).
22.83%, respectively. Structure refinement statistics are summa- Improved methods for binding protein models in electron density
rized in Supplemental Table S1. maps and the location of errors in these models. Acta Crystallogr.
Molecular superimpositions and rms deviation calculations were A 47, 110–119.
performed with FIT (G. Lu, http://bioinfo1.mbfys.lu.se/guoguang/
Kenworthy, A.K., and Edidin, M. (1998). Distribution of a glycosyl-fit.html). Structure-based sequence alignment was rendered with
phosphatidylinositol-anchored protein at the apical surface ofthe program ESPript (Gouet et al., 1999). Molecular surfaces were
MDCK cells examined at a resolution of 100 A using imaginggenerated with grasp (Nicholls et al., 1991) or Pymol (DeLano W.L.,
fluorescence resonance energy transfer. J. Cell Biol. 142, 69–84.http://www.pymol.org). Ribbon diagrams were generated with Setor
(Evans, 1993). Kissinger, C.R., Gehlhaar, D.K., and Fogel, D.B. (1999). Rapid auto-
mated molecular replacement by evolutionary search. Acta Crys-
tallogr. D Biol. Crystallogr. 55, 484–491.Acknowledgments
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